Associations between P53 Arg72Pro and development of digestive tract cancers: A meta-analysis

Archives of Medical Research

Volumn 42, Issue 1, 2011, Pages 60-69

  Liu, Liu ^a   Wang, Kai ^a   Zhu, Zheng Ming ^a   Shao, Jiang Hua ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Colorectal cancer; Esophageal cancer; Gallbladder cancer; Hepatocellular cancer; Meta analysis; P53 gene; Pancreatic cancer; Polymorphism

Indexed keywords

PROTEIN P53; PROTEIN P53 ARG72PRO; UNCLASSIFIED DRUG;

ARTICLE; ASIAN; CANCER RISK; CASE CONTROL STUDY; COLON CANCER; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DISEASE CARRIER; GALLBLADDER CANCER; HUMAN; PANCREAS CANCER; STOMACH CANCER;

ARGININE; ASIAN CONTINENTAL ANCESTRY GROUP; DATABASES, FACTUAL; DIGESTIVE SYSTEM NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79952075302     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2011.01.008     Document Type: Article

References (81)

1. Jemal A., Siegel R., Xu J., et al. Cancer Statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Jemal A., Thomas A., Murray T., et al. Cancer statistics, 2002. CA Cancer J Clin 2002, 52:23-47.
3. Navarro Silvera S.A., Mayne S.T., Risch H., et al. Food group intake and risk of subtypes of esophageal and gastric cancer. Int J Cancer 2008, 123:852-860.
4. Parkin D.M., Olsen A.H., Sasieni P. The potential for prevention of colorectal cancer in the UK. Eur J Cancer Prev 2009, 18:179-190.
5. Pham T.M., Fujino Y., Kikuchi S., et al. Dietary patterns and risk of stomach cancer mortality: the Japan collaborative cohort study. Ann Epidemiol 2010, 20:356-363.
6. Liu L., Zhuang W., Wang C., et al. Interleukin-8 -251 A/T gene polymorphism and gastric cancer susceptibility: a meta-analysis of epidemiological studies. Cytokine 2010, 50:328-334.
7. Dong J., Dai J., Zhang M., et al. Potentially functional COX-2-1195G>A polymorphism increases the risk of digestive system cancers: a meta-analysis. J Gastroenterol Hepatol 2010, 25:1042-1050.
8. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992, 52:6735-6740.
9. Ren J.S., Freedman N.D., Kamangar F., et al. Tea, coffee, carbonated soft drinks and upper gastrointestinal tract cancer risk in a large United States prospective cohort study. Eur J Cancer 2010, 46. 1873-1381.
10. Imyanitov E.N. Gene polymorphisms, apoptotic capacity and cancer risk. Hum Genet 2009, 125:239-246.
11. Hollstein M., Sidransky D., Vogelstein B., et al. p53 mutations in human cancers. Science 1991, 253:49-53.
12. Matlashewski G.J., Tuck S., Pim D., et al. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987, 7:961-963.
13. Zhou Y., Li N., Zhuang W., et al. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer 2007, 121:1481-1486.
14. Tang N.P., Wu Y.M., Wang B., et al. Systematic review and meta-analysis of the association between P53 codon 72 polymorphism and colorectal cancer. Eur J Surg Oncol 2010, 36:431-438.
15. Wang B., Wang D., Zhang D., et al. Pro variant of TP53 Arg72Pro contributes to esophageal squamous cell carcinoma risk: evidence from a meta-analysis. Eur J Cancer Prev 2010, 19:299-307.
16. Kim N., Cho S.I., Lee H.S., et al. The discrepancy between genetic polymorphism of p53 codon 72 and the expression of p53 protein in Helicobacter pylori-associated gastric cancer in Korea. Dig Dis Sci 2010, 55:101-110.
17. Kawajiri K., Nakachi K., Imai K., et al. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 1993, 14:1085-1089.
18. Kim J.M., Lee O.Y., Lee C.G., et al. P53 Codon 72 and 16-bp duplication polymorphisms of gastric cancer in Koreans. Korean J Gastroenterol 2007, 50:292-298. [Korean].
19. Cao Y.Y., Ge H., Chen L.Q., et al. Correlation of 53BP1 and p53 polymorphisms to susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenoacarcinoma. Aizheng 2007, 26:1052-1057. [Chinese].
20. Yang M., Guo Y., Zhang X., et al. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 2007, 28:1996-2001.
21. Capella G., Pera G., Sala N., et al. DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study. Int J Epidemiol 2008, 37:1316-1325.
22. Gomes de Souza L., Miranda de Lima J., Dale Cotrim Guerreiro da Silva I., et al. P53 Arg72Pro polymorphism in gastric cancer patients. J Gastrointest Cancer 2009, 40:41-45.
23. De Feo E., Persiani R., La Greca A., et al. A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression. Mutat Res 2009, 675:60-65.
24. Mojtahedi Z., Haghshenas M.R., Hosseini S.V., et al. p53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients. Indian J Cancer 2010, 47:31-34.
25. Zhu K.X., Li Y.M., Wen X.L., et al. Association of P53 Arg72Pro polymorphism and Helicobacter pylori infection with risk of gastric cancer in a high incidence area in China. Shijie Huaren Xiaohua Zazhi 2009, 17:3734-3739. [Chinese].
26. Lu K.H. Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis. Fam Cancer 2008, 7:53-58.
27. Taioli E., Bonassi S. Methodological issues in pooled analysis of biomarker studies. Mutat Res 2002, 512:85-92.
28. Zintzaras E. Impact of Hardy-Weinberg equilibrium deviation on allele-based risk effect of genetic association studies and meta-analysis. Eur J Epidemiol 2010, 25:553-560.
29. Hamajima N., Matsuo K., Suzuki T., et al. No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett 2002, 181:81-85.
30. Economopoulos K.P., Sergentanis T.N. Need for clarification of data in the recent meta-analysis about p53 polymorphism and gastric cancer risk. Int J Cancer 2010, 126:2509.
31. Lee J.M., Lee Y.C., Yang S.Y., et al. Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer 2000, 89:458-464.
32. Zhang L., Xing D., He Z., et al. P53 gene codon 72 polymorphism and susceptibility to esophageal squamous cell carcinoma in a Chinese population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2002, 19:10-13. [Chinese].
33. Li T., Lu Z.M., Guo M., et al. p53 codon 72 polymorphism (C/G) and the risk of human papillomavirus-associated carcinomas in China. Cancer 2002, 95:2571-2576.
34. Vos M., Adams C.H., Victor T.C., et al. Polymorphisms and mutations found in the regions flanking exons 5 to 8 of the TP53 gene in a population at high risk for esophageal cancer in South Africa. Cancer Genet Cytogenet 2003, 140:23-30.
35. Zhang J.H., Li Y., Wang R., et al. P53 gene polymorphism with susceptibility to esophageal cancer and lung cancer in a Chinese population. Zhonghua Zhong Liu Za Zhi 2003, 25:365-367. [Chinese].
36. Hong Y., Miao X., Zhang X., et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005, 65:9582-9587.
37. Cai L., Mu L.N., Lu H., et al. Dietary selenium intake and genetic polymorphisms of the GSTP1 and p53 genes on the risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2006, 15:294-300.
38. Liu G., Cescon D.W., Zhai R., et al. p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma. Dis Esophagus 2010, 23:36-39.
39. Hiyama T., Tanaka S., Kitadai Y., et al. p53 Codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. Int J Cancer 2002, 100:304-308.
40. Zhang Z.W., Newcomb P., Hollowood A., et al. Age-associated increase of codon 72 arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. Clin Cancer Res 2003, 9:2151-2156.
41. Mu L.N., Zhou X.F., Ding B.G., et al. Genetic polymorphisms of p53 codon 72 and the risk of gastric cancer. ZhongGuo AiZheng ZaZhi 2003, 13. [Chinese].
42. Wu M.T., Chen M.C., Wu D.C. Influences of lifestyle habits and p53 codon 72 and p21 codon 31 polymorphisms on gastric cancer risk in Taiwan. Cancer Lett 2004, 205:61-68.
43. Shen H., Solari A., Wang X., et al. P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep 2004, 11:1115-1120.
44. Lai K.C., Chen W.C., Jeng L.B., et al. Association of genetic polymorphisms of MK, IL-4, p16, p21, p53 genes and human gastric cancer in Taiwan. Eur J Surg Oncol 2005, 31:1135-1140.
45. Perez-Perez G.I., Bosques-Padilla F.J., Crosatti M.L., et al. Role of p53 codon 72 polymorphism in the risk of development of distal gastric cancer. Scand J Gastroenterol 2005, 40:56-60.
46. Yi S.Y., Lee W.J. A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer. World J Gastroenterol 2006, 12:6536-6539.
47. Sul J., Yu G.P., Lu Q.Y., et al. P53 codon 72 polymorphisms: a case-control study of gastric cancer and potential interactions. Cancer Lett 2006, 238:210-223.
48. Chung W.C., Lee K.M., Lee B.I., et al. P53 genetic polymorphism of gastric cancer in Korea. Korean J Intern Med 2006, 21:28-32.
49. Olschwang S., Laurent-Puig P., Vassal A., et al. Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. Hum Genet 1991, 86:369-370.
50. Sjalander A., Birgander R., Athlin L., et al. P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 1995, 16:1461-1464.
51. Murata M., Tagawa M., Kimura M., et al. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients;discrete results with smoking history. Carcinogenesis 1996, 17:261-264.
52. Sayhan N., Yazici H., Budak M., et al. P53 codon 72 genotypes in colon cancer. Association with human papillomavirus infection. Res Commun Mol Pathol Pharmacol 2001, 109:25-34.
53. Gemignani F., Moreno V., Landi S., et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004, 23:1954-1956.
54. Schneider-Stock R., Boltze C., Peters B., et al. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia 2004, 6:529-535.
55. Lima J.M., Serafim P.V., Silva I.D., et al. Role of the genetic polymorphism of p53 (codon 72) gene in colorectal cancer. Arq Gastroenterol 2006, 43:8-13. [Portuguese].
56. Koushik A., Tranah G.J., Ma J., et al. p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer 2006, 119:1863-1868.
57. Perez L.O., Abba M.C., Dulout F.N., et al. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 2006, 12:1426-1429.
58. Perfumo C., Bonelli L., Menichini P., et al. Increased risk of colorectal adenomas in Italian subjects carrying the p53 PIN3 A2-Pro72 haplotype. Digestion 2006, 74:228-235.
59. Tan X.L., Nieters A., Hoffmeister M., et al. Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction?. Pharmacogenet Genomics 2007, 17:639-6345.
60. Zhu Z.Z., Wang A.Z., Jia H.R., et al. Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol 2007, 37:385-390.
61. Dastjerdi M., Salehi M., Mohajeri M., et al. Evidence for an association of TP53 codon 72 polymorphism with sporadic colorectal cancer risk in Isfahan. JRMS 2008, 13:317-323.
62. Csejtei A., Tibold A., Varga Z., et al. GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. Anticancer Res 2008, 28:1917-1922.
63. Polakova V., Pardini B., Naccarati A., et al. Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic. Hum Mutat 2009, 30:661-668.
64. Cao Z., Song J.H., Park Y.K., et al. The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients. Neoplasma 2009, 56:114-118.
65. Anzola M., Cuevas N., Lopez-Martinez M., et al. Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett 2003, 193:199-205.
66. Leveri M., Gritti C., Rossi L., et al. Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Cancer Lett 2004, 208:75-79.
67. Zhu Z.Z., Cong W.M., Liu S.F., et al. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol 2005, 11:289-292.
68. Ezzikouri S., El Feydi A.E., Chafik A., et al. The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in a Moroccan population. Hepatol Res 2007, 37:748-754.
69. Peng T., Yan L., Liu Z., et al. P52 codon72 polymorphism is closely associated with risk of hepatocellular cancer among Guangxi people. ZhongHua Waike ZaZhi 2004, 42:313-314. [Chinese].
70. Tsuchiya Y., Kiyohara C., Sato T., et al. Polymorphisms of cytochrome P450 1A1, glutathione S-transferase class mu, and tumour protein p53 genes and the risk of developing gallbladder cancer in Japanese. Clin Biochem 2007, 40:881-886.
71. Tsuchiya Y., Baez S., Calvo A., et al. Evidence that genetic variants of metabolic detoxication and cell cycle control are not related to gallbladder cancer risk in Chilean women. Int J Biol Markers 2010, 25:75-78.
72. Naccarati A., Pardini B., Polakova V., et al. Genotype and haplotype analysis of TP53 gene and the risk of pancreatic cancer: an association study in the Czech Republic. Carcinogenesis 2010, 31:666-670.
73. Attia J., Thakkinstian A., D'Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol 2003, 56:297-303.
74. Klug S.J., Ressing M., Koenig J., et al. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol 2009, 10:772-784.
75. Fleiss J.L. Analysis of data from multiclinic trials. Control Clin Trials 1986, 7:267-275.
76. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965, 64:31-49.
77. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
78. Ioannidis J.P., Ntzani E.E., Trikalinos T.A., Contopoulos-Ioannidis D.G. Replication validity of genetic association studies. Nat Genet 2001, 29:306-309.
79. Thomas M., Kalita A., Labrecque S., et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999, 19:1092-1100.
80. Storey A., Thomas M., Kalita A., et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998, 393:229-234.
81. Dai S., Mao C., Jiang L., et al. P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies. Hum Genet 2009, 125:633-638.